Afatinib is an oral irreversible ErbB family blocker being investigated as a potential treatment for a variety of solid tumours [1], including epidermal growth factor receptor (EGFR)-mutation-positive non-small cell lung cancer (NSCLC), and metastatic head and neck cancer [2–6]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.